Author: devcuration

Parabilis Medicines just put a very exact number on a very uncomfortable problem. $305M in Series F capital, closed Jan 8, 2026, oversubscribed, premium valuation, no theatrics. This is what happens when a company spends a decade walking straight at biology most people labeled undruggable and then shows up with human data that refuses to be ignored. Parabilis Medicines started as FogPharma in 2015, built from Gregory Verdine’s conviction that intracellular protein interactions were not impossible, just inconvenient. Years in a Harvard lab turned into stapled peptides, which evolved into Helicon peptides, which became a platform that actually gets inside…

January 8, 2026 did not whisper. It exhaled. Alveus Therapeutics stepped into the public markets with a $151.7M Series A and the kind of calm confidence that usually only shows up after decades of scar tissue. Founded by New Rhein Healthcare Investors, this was not a debut built on noise. It was built on oxygen. The kind that keeps a system alive when the rest of the room is gasping for air and calling it momentum. Obesity medicine has been loud lately. Weekly injections. Fast drops. Faster headlines. Then comes the quiet part no one likes to sit with. Weight…

Pomelo Care just closed a $92M Series C at a $1.7B valuation, and this one lands different. Not louder. Not softer. Sharper. This is what happens when clinical evidence, payer economics, and operational discipline stop circling each other and finally lock in. Healthcare usually improvises. Pomelo Care moves in time. Founded in 2021 by Marta Bralic Kerns, Pomelo Care stepped into a system where women and children were expected to navigate fragmented care like it was a character-building exercise. Instead of asking patients to hustle harder, Pomelo Care built infrastructure that does the heavy lifting, pairing data science with clinicians…

There are healthcare companies that chase attention, and then there are companies that chase outcomes. Carna Health never looked for the spotlight. It looked for the disease. Founded in Boston in April 2021, Carna Health built itself around a global truth most systems prefer not to sit with: chronic kidney disease does not wait for modern infrastructure, and it does not care about borders. Affecting 1 in 10 adults worldwide and projected to become the 5th leading cause of death by 2040, CKD is not a specialty problem. It is a population problem hiding in plain sight. That mindset starts…

Semafor just priced its first real round, and the number matters less than the signal. $30M raised. $330M post. Profitable in year 3. In news media. In this economy. If that makes you shift in your chair, good. That tension is the sound of an old model realizing the future already RSVP’d and did not ask permission. Justin B. Smith and Ben Smith did not build Semafor to chase clicks, juice outrage, or beg algorithms for mercy. They built it for people who actually move money, policy, and consequence. The global leadership class. C-suite operators, heads of state, senior policymakers.…

xAI did not just raise capital. It bent gravity. $20B in Series E funding announced Jan 6, 2026, pushing valuation to ~230B, and suddenly the word scale feels like a polite understatement. This is an AI company founded in March 2023 with a mission to understand the true nature of the universe, now operating the largest coherent GPU cluster on Earth out of Memphis, TN. Two years ago that sentence sounded like science fiction with a pitch deck. Today it reads like a status report. On July 18, 2025, we announced xAI’s previous funding when velocity was the headline. Since…

January 8, 2026 shows Vizgen doing exactly what the name promises: sharpening the picture until the biology stops arguing back. A $48M financing led by ARCH Venture Partners, with M Ventures and Northpond Ventures co-leading, signals that spatial biology is no longer a science fair project. The market is focusing the lens, locking onto signal, and deciding this category deserves grown-up capital and grown-up expectations. This did not start as a funding story. It started nearly a decade ago in a Harvard lab where Xiaowei Zhuang built MERFISH with the kind of discipline that ignores hype cycles and waits for…

Luxury Presence started with a quiet contradiction the real estate world has learned to live with. The agents moving the most volume were often buried under the weakest tools. Too many tabs, too much manual work, not enough signal. Back in 2016, a conversation between Jade Mills and Malte Kramer put that tension into focus. Luxury branding on the outside, outdated systems underneath. That friction became the origin story, and now the company just announced a $22M Series C led by Bessemer Venture Partners, paired with a $15M debt facility from J.P. Morgan, bringing total equity funding to $89M and…

January always tells the truth if you know how to listen. The volume drops, the scoreboard resets, and what remains is execution. Presto Phoenix just spoke clearly, closing a $10M growth round led by Metropolitan Partners Group, joined by Remus Capital, Link Ventures, and strategic angels including ElevenLabs CEO Mati Staniszewski. Not a comeback tour. More like a controlled burn followed by lift. Presto Phoenix exists because gravity is optional when you know the math. Founded in Oct 2008 by Rajat Suri, who traded an MIT doctoral path for an apron and a front row seat to restaurant reality, this…

In 2021, a quiet idea took shape around a loud, inconvenient truth. Roughly 40% of the human proteome lives outside the cell, visible, influential, and mostly untouched by modern degradation tools. EpiBiologics did not show up to admire the gap. They showed up to close it. Publicly launched in March 2023 out of San Mateo, California, the company was built on decades of work from Dr. James Allen Wells at the University of California, San Francisco, with a mindset that biology does not care about convenience, and neither should drug design. Dr. James Allen Wells is not a novelty act.…